Whole Blood Platelet Function in Acute Ischemic Stroke

Importance of Dense Body Secretion and Effects of Antithrombotic Agents

Rajiv Joseph, MD, G. D’Andrea, MD, S.B. Oster, and K.M.A. Welch, MD

We studied platelet function in whole blood, a situation that better reflects the in vivo state, from 85 patients with acute ischemic stroke and from 19 healthy controls. Patients receiving no antithrombotic drugs demonstrated increased platelet dense body secretion without an associated increase in platelet aggregation, thus raising the possibility that dense body secretion may be of separate importance in cerebral infarction. Our results also suggest that dense body secretion may occur independently of aggregation. Heparin and heparin plus warfarin were ineffective in reducing the high level of dense body secretion seen in acute cerebral infarction, whereas treatment with aspirin plus dipyridamole inhibited both dense body secretion and platelet aggregation. It seems worthwhile to investigate the usefulness of antiplatelet drugs in the treatment of acute ischemic stroke wherein clinical outcome is correlated with the extent of suppression of platelet dense body secretion. (Stroke 1989;20:38–44)

Normal platelet function includes dense body secretion and aggregation.1 While it is generally considered that platelets may contribute to the pathogenesis and/or propagation of cerebral infarction by forming occlusive aggregates,2–5 the role of vasoactive platelet dense body release products has been less frequently studied. Therefore, we simultaneously investigated platelet dense body secretion and aggregation in whole blood, which better reflects the natural milieu, from patients suffering acute ischemic stroke and from healthy controls.

Even though platelet and coagulation functions are frequently regarded as separate processes in hemostasis, they are in fact closely linked6 so that simultaneous suppression of platelet activity may be necessary to fully inhibit thrombosis. The limited value of heparin and warfarin, potent inhibitors of thrombin generation, in the treatment of acute cerebral ischemia7 therefore may be in part due to inadequate suppression of platelet activity. To date there is little information from stroke patients concerning the effects of antithrombotic agents on platelet activity, particularly dense body secretion, that would support this contention. Accordingly, we have also studied the effects of heparin, heparin plus warfarin, and aspirin plus dipyridamole on platelet dense body secretion and aggregation in whole blood from patients with acute ischemic stroke.

Subjects and Methods

We studied 85 consecutive patients with acute ischemic stroke admitted to the stroke unit of the Department of Neurology, Henry Ford Hospital, Detroit, Michigan (stroke group) and 19 healthy controls (control group) (age 40±20 years, 37% male, hematocrit 40±6%). All values are expressed as mean±SD. All 104 subjects were without a known primary platelet or coagulation disorder. Ischemic stroke was diagnosed based on a history of the sudden onset of a persistent focal neurologic deficit lasting for >24 hours. Computed tomography (CT) helped exclude hemorrhage. The stroke group was divided into four subgroups based on infarct size and treatment (see below), and the control group was divided into two subgroups based on age (age <40 years, n=12; age >41 years, n=7).

Based on the absence of clinical signs of cortical involvement (language impairment, neglect, cortical sensory loss), 56 of the 85 patients were diagnosed as having suffered small subcortical infarcts attributed to small-vessel disease; this was supported by CT in 38 patients (68%), and the remaining 18 (32%) had negative CT scans. These 56
patients were randomly assigned to treatment with
400±140 mg aspirin/day plus 186±51 mg dipyridamole/day (AD subgroup, n=29, age 65±15 years, 62% male, hematocrit 42±6%, 69% positive scans) or no drugs (ND subgroup, n=27, age 66±13 years, 59% male, hematocrit 38±2%, 67% positive scans) before the study. Patients in the AD subgroup were treated for 1–10 days before the study; 6.4±5.6 days had elapsed from the onset of neurologic dysfunction. Twenty AD patients (69%) were hypertensive, seven (24%) had diabetes mellitus, and 10 (34%) smoked. Patients in the ND subgroup took no antiplatelet medication before the study; 4.2±3.7 days had elapsed from the onset of neurologic dysfunction. Twenty ND patients (74%) were hypertensive, seven (26%) had diabetes mellitus, and seven (26%) smoked. Of the 27 ND patients, nine were younger than 60, seven were aged 61–70, and 11 were older than 71 years; 48 hours had elapsed from the onset of neurologic dysfunction in eight, 60–120 hours in eight, and >6 days in 11.

Based on the presence of clinical signs of cortical involvement (see above), 29 of the 85 patients were diagnosed as having suffered cortical infarcts attributed to large-vessel occlusion; this was supported by CT in 17 patients (59%), and the remaining 12 (41%) had negative CT scans even though the clinical signs were consistent with a cortical infarction. These 29 patients were randomly assigned to treatment with intravenous infusion of 1007±341 units heparin/hr (H subgroup, n=18, age 66±9 years, 67% male, hematocrit 44±6%, 56% positive scans) or intravenous infusion of 913±352 units heparin/hr plus 8.6±2.2 mg warfarin/day (WH subgroup, n=11, age 65±13 years, 36% male, hematocrit 40±4%, 64% positive scans). Patients in the H subgroup were treated for 1–10 days before the study; 4.8±1.9 days had elapsed from the onset of neurologic dysfunction. Fourteen H patients (78%) were hypertensive, three (17%) had diabetes mellitus, and 10 (56%) smoked. Patients in the WH subgroup were treated for 1–10 days before the study; 6±2.7 days had elapsed from the onset of neurologic dysfunction. Six WH patients (55%) were hypertensive, two (18%) had diabetes mellitus, and three (27%) smoked.

Antihypertensive and antidiabetic drug therapies were matched between all the subgroups. Platelet function in whole blood was studied within 10 days after the onset of neurologic dysfunction.

Peripheral venous blood (10 ml from the antecubital vein) from each subject was collected into one-tenth its volume of 3.8% sodium citrate. Whole blood was diluted with an equal volume of 0.9% isotonic saline, and the hematocrit was estimated. No adjustments were made to achieve a fixed hematocrit. Platelet dense body secretion (release of adenosine triphosphate, ATP release) and aggregation were measured simultaneously in diluted whole blood using the Model 500 Chrono-Log Lumiaggrometer (Havertown, Pennsylvania).

ATP release was measured using the luminescence principle. Firefly luminous organ extracts that have become dark react in a dose-dependent fashion to added ATP by producing light. ATP released from platelets is reliably estimated by this system. Aliquots of 900 μl diluted whole blood were placed in cuvettes, warmed for 2–3 minutes at 37°C in the

**Figure 1.** Representation of platelet aggregation and dense body secretion (ATP release) in 50% diluted whole blood in response to collagen induction. Secretion always preceded aggregation. Sec.-Lag-Agg., time in seconds between onset of ATP release and onset of aggregation. See text for details of measurements.
aggregometer heater block, and stirred at 1200 rpm using a Teflon-coated magnetic stirrer bar; 100 μl (4 mg) luciferase-luciferin reagent (Chrono-Log Corp. #395) was added for estimating ATP release. The maximum height of the ATP release curve was derived from internal ATP standard concentrations in picomoles per 900 μl diluted whole blood.

The principle of whole-blood aggregometry involves measuring the electrical resistance (impedance) to the passage of a small electric current across two platinum electrodes immersed in a sample of blood. Following initial immersion, the electrodes become coated with a layer of platelets. The addition of an inducing agent results in further accumulation of platelets on the electrodes, simultaneously increasing the impedance across them. This change in impedance is recorded on a strip chart recorder. Collagen is a potent platelet-stimulating agent acting directly on platelets. It may be the principal thrombogenic stimulus in ulcerated atherosclerotic plaques. Accordingly, native collagen derived from equine tendon (Chrono-Log Corp. #380) used as the inducing agent was applied in final concentrations of 1, 2, and 4 μg/ml. For measuring aggregation, the gain of the aggregometer was calibrated at 12 mm=5 Ω.

As indicators of platelet dense body secretion (ATP release), the following measurements were made on each set of tracings based on modifications of our previous studies12,13: secretion lag time (SLT), time in seconds from the addition of collagen to the start of ATP release; 0–30-second secretion slope (SS 0–30) (xᵢ/yᵢ in Figure 1), slope of the ATP release curve between the onset of ATP release (time 0) and a point 30 seconds later; 30–60-second secretion slope (SS 30–60) (xᵢ/yᵢ in Figure 1), slope of the ATP release curve between 30 and 60 seconds after time 0; time in seconds to achieve half-maximal ATP release after addition of collagen (SED/50), twice SED/50 was considered to be the time to reach the peak height of the ATP release curve; secretion peak height (SPH), the maximum height of the ATP release curve relative to a curve derived from ATP standard concentrations in picomoles per 900 μl diluted whole blood. As indicators of platelet aggregation, the following measurements were made on each set of tracings based on modifications of our previous studies12,13: aggregation lag time (ALT), time in seconds from the addition of collagen to the start of aggregation; 0–60-second aggregation slope (AS 0–60) (xᵢ/yᵢ in Figure 1), slope of the aggregation curve between the onset of aggregation (time 0) and a point 60 seconds later; 60–120-second aggregation slope (AS 60–120) (xᵢ/yᵢ in Figure 1), slope of the aggregation curve between 60 and 120 seconds after time 0; 120–180-second aggregation slope (AS 120–180) (xᵢ/yᵢ in Figure 1), slope of the aggregation curve between 120 and 180 seconds after time 0; time in seconds to achieve half-maximal aggregation after addition of collagen (AED/50), twice AED/50 was considered to be the time to reach the peak height of the aggregation curve; aggregation peak height (APH), the maximum height of the aggregation curve in units of electrical resistance (ohms). As an indicator of the relation between platelet dense body secretion and aggregation, the time in seconds between the onset of ATP release and the onset of aggregation (secretion-lag-aggregation, SLA) was measured on each set of tracings; secretion always preceded aggregation. These 12 platelet function variables allowed reconstruction of secretion and aggregation graphs for each subgroup based on their mean±SEM, permitting comparison of the “entire” platelet dense body secretion and aggre-
We used profile analysis to test for differences between subgroups across the three collagen concentrations. If an overall difference was significant by profile analysis, then pairwise comparisons using two-sample t tests were done adjusting for multiple testing (0.05/3 = 0.016). Comparisons were made to determine the effect of age and time after stroke onset in controls and ND patients. The control group was compared with the ND subgroup, and the ND subgroup was compared with the AD, H, and WH subgroups separately.

Results

Within the control group, the overall difference between subgroups was not significant for any platelet function variable, and no sex-related effects on platelet function were observed. The effect of collagen on platelet dense body secretion and aggregation was concentration-dependent.

There were no significant differences for any platelet function variable among the ND patients when the subgroup was further stratified by age. Even though we observed no age-related effects on platelet function in the controls or the ND patients, we used analysis of covariance before comparing platelet function in the control group with that in the ND subgroup. Platelet dense body secretion was increased in the ND subgroup compared with the control group at all three collagen concentrations (Figure 2), but platelet aggregation was similar (Figure 3, Table 1).

Table 1. Platelet Function Variables in Whole Blood From Stroke Patients

<table>
<thead>
<tr>
<th>Platelet function variable (mean±SD of collagen concentrations 1, 2, and 4 mg/ml)</th>
<th>Time course</th>
<th>Profile analysis (p value)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control (n=19)</td>
<td>ND (n=27)</td>
</tr>
<tr>
<td>Secretion (ATP release)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lag time (sec)</td>
<td>24±8</td>
<td>22±6</td>
</tr>
<tr>
<td>Slope 0–30 (pM/sec)</td>
<td>7.5±6.2</td>
<td>10.6±7.7</td>
</tr>
<tr>
<td>Slope 30–60 (pM/sec)</td>
<td>10.7±7.3</td>
<td>13.9±7.3</td>
</tr>
<tr>
<td>ED/50 (sec)</td>
<td>61±17</td>
<td>65±16</td>
</tr>
<tr>
<td>Peak height (pM)</td>
<td>621±360</td>
<td>923±329</td>
</tr>
<tr>
<td>Aggregation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lag time (sec)</td>
<td>45±17</td>
<td>51±19</td>
</tr>
<tr>
<td>Slope 0–60 (fL/sec)</td>
<td>0.20±0.05</td>
<td>0.22±0.08</td>
</tr>
<tr>
<td>Slope 60–120 (fL/sec)</td>
<td>0.14±0.04</td>
<td>0.16±0.03</td>
</tr>
<tr>
<td>Slope 120–180 (fL/sec)</td>
<td>0.09±0.02</td>
<td>0.10±0.02</td>
</tr>
<tr>
<td>ED/50 (sec)</td>
<td>141±31</td>
<td>149±38</td>
</tr>
<tr>
<td>Peak height (fL)</td>
<td>34±6</td>
<td>37±7</td>
</tr>
<tr>
<td>Relation</td>
<td>Lag (sec)</td>
<td>21±12</td>
</tr>
</tbody>
</table>

All values per 900 µl of 50% diluted blood. ND, no drug; H, 1007±341 units heparin/hr for 1–10 days; WH, 8.6±2.2 mg warfarin/day plus 913±352 units heparin/hr for 1–10 days; AD, 400±140 mg aspirin/day plus 186±51 mg dipyridamole/day for 1–10 days; ED/50, time to achieve half-maximal value; Lag, time between onset of secretion measured by ATP release and onset of aggregation; NS, not significant. Time after onset of neurologic dysfunction. Profile analysis across three collagen concentrations (1, 2, and 4 µg/ml) was used to compare differences between control and ND patients, within the ND group based on time after onset of stroke, and between the ND group and treated subgroups (H, WH, and AD). Compared with control, platelet secretion was increased in ND patients (Figure 2) without alteration of aggregation (Figure 3). Compared with ND patients, H patients showed only decreased platelet aggregation, WH patients showed no inhibition of platelet activity, and only AD patients showed decreased platelet secretion and aggregation.
There were no significant differences for any platelet function variable among the ND patients when the subgroup was further stratified by time elapsed from the onset of neurologic dysfunction. The overall differences within the ND subgroup among collagen concentrations was significant for all platelet function variables except SS 30-60. The means of all variables reflected increased platelet dense body secretion at <48 hours that decreased at 60-120 hours and then began increasing at >6 days after the onset of neurologic dysfunction; the results were significant for AS 0-60 and AS 120-180 (Table 1).

Compared with the ND subgroup, the H subgroup showed only decreased platelet aggregation at all three collagen concentrations (Figure 4, Table 1). Treatment with heparin did not reduce the increased platelet dense body secretion seen after acute cerebral ischemia. No difference was observed between the ND and WH subgroups for secretion or aggregation at any collagen concentration (Figure 4, Table 1). Compared with the ND subgroup, platelet secretion and aggregation were both decreased in the AD subgroup at all three collagen concentrations (Figure 4, Table 1); SLA was also prolonged in the AD subgroup at all three collagen concentrations (Figure 5, Table 1). Of the antithrombotic agents studied, only treatment with aspirin plus dipyridamole reduced both secretion and aggregation.

Discussion

Studying platelet function in whole blood, we have shown an increase in platelet dense body secretion without a simultaneous increase in platelet aggregation in patients suffering cerebral infarction. Previous studies have shown increased platelet aggregation in acute ischemic stroke by techniques requiring the use of platelet-rich plasma, an approach that appears to poorly reflect the in vivo state. Study of platelet function in whole blood reflects the in vivo state better since it allows assessment of platelet activity while still in its natural milieu. It is now known that other cellular elements in blood (erythrocytes and leukocytes in particular) may significantly affect platelet function. Furthermore, epinephrine, a potent inducer of platelet aggregation in platelet-rich plasma, does not function as such in whole blood. Several studies have shown the impedance technique to be reliable in assessing platelet dense body secretion and aggregation in whole blood. Therefore, our results may better reflect in vivo platelet function in acute ischemic stroke patients.

A common sequence of events, the basic platelet reaction, is believed to follow platelet activation. Platelet dense body and α-granule release are believed to precede irreversible aggregation, that is,
by guest on October 30, 2017 http://stroke.ahajournals.org/ Downloaded from

proteins.32-33 Thus, our article adds to the body of
no known functional significance for these
thromboglobulin and platelet factor 4, but there is
in stroke patients based on the release of
p-
has been documented previously to be increased
aggregates.28-31 Platelet secretion from the α-granule
ritory, probably mediated by platelet release prod-
products and unassociated with occlusive platelet
aggregates.28-31 Platelet secretion from the α-granule
in whole blood. This inhibition extended to nearly all platelet
function variables studied and was significantly
more marked than that of heparin or heparin plus
warfarin. Even though recent experience suggests
that aspirin treatment does not alter long-term prog-
nosis in stroke patients,35 the clinical benefit of
adding antiplatelet drugs to the treatment regimen
of acute stroke has not been assessed previously.36
nor is it addressed in our study. However, based on
the platelet function data that we obtained, it seems
worthwhile to investigate the usefulness of aspirin
alone or with dipyridamole37 in the treatment of
acute ischemic stroke, wherein clinical outcome is
correlated with the extent of suppression of platelet
dense body secretion.

We next investigated the effect of currently used
antithrombotic agents on platelet function, particu-
larly dense body secretion, in whole blood. Aspirin
plus dipyridamole inhibited whereas heparin and
heparin plus warfarin had no effect on platelet dense
body secretion. Aspirin plus dipyridamole also inhib-
ited platelet aggregation, as did heparin. The effects
of heparin and heparin plus warfarin we noted were
observed in patients judged on a clinical basis to
have suffered large cortical infarcts, unlike the
unmedicated stroke patients, who had small subcor-
tical infarcts. However, it is sometimes difficult to
clearly distinguish cortical from subcortical inf-
archs, and we believe that pathophysiologic mech-
isms for stroke in at least some of these patients
were mixed. Moreover, in a recent study involving
measurement of cytosolic ionized calcium in unmed-
icated subjects with "cortical" and "subcortical"
stroke, no differences were observed in platelet
function.34

Of the antithrombotic agents we investigated,
only aspirin plus dipyridamole reduced both platelet
dense body secretion and aggregation in whole
blood. This inhibition extended to nearly all platelet
function variables studied and was significantly
more marked than that of heparin or heparin plus
warfarin. Even though recent experience suggests
that aspirin treatment does not alter long-term prog-
nosis in stroke patients,35 the clinical benefit of
adding antithrombotic agents to the treatment regimen
of acute stroke has not been assessed previously.36
nor is it addressed in our study. However, based on
the platelet function data that we obtained, it seems
worthwhile to investigate the usefulness of aspirin
alone or with dipyridamole37 in the treatment of
acute ischemic stroke, wherein clinical outcome is
correlated with the extent of suppression of platelet
dense body secretion.

Acknowledgments

The authors wish to express their gratitude to Dr. Daniel A. Walz for reading the manuscript. The authors also wish to thank Dr. Steven R. Levine and Mr. S. Grunfeld for helpful suggestions and Ms. Hally Phelps for secretarial assistance in preparing the manuscript.
References


**Key Words** • aspirin • diprydamole • heparin • platelet aggregation • warfarin
Whole blood platelet function in acute ischemic stroke. Importance of dense body secretion and effects of antithrombotic agents.
R Joseph, G D’Andrea, S B Oster and K M Welch

Stroke. 1989;20:38-44
doi: 10.1161/01.STR.20.1.38
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1989 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/20/1/38

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/